U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07057349) titled 'CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer' on June 30.
Brief Summary: Single-center with the option to expand to multi-center, international, open label, non-randomized, multiple-dose, multi-cohort study, in participants with metastatic or unresectable cancer. Eligible participants will receive an initial injection of [18F]CSB-321 followed by PET imaging prior to administration of the I-O therapy and a second and third injection post treatment each with PET imaging. The images will be analyzed for the distribution of radioactivity. Participants will be followed for adverse events up to 3-4 hours post injection. Avail...